https://doi.org/10.4081/itjm.2020.1348
Antithrombotic drugs with adjuvant action against COVID-19
Accepted: 31 August 2020
HTML: 13
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Waiting for the vaccine and/or the best antiviral treatment for coronavirus infection disease 2019 (COVID-19), after its outbreak in China at the beginning of 2020 and its viral diffusion around the world in the following weeks, several drugs have been suggested for their potential adjuvant support against infection. Several drugs have been suggested to have a potential ancillary antiviral role. Circulating proteins, in particular proteases and peptidases regulated by drug functions, may interact with well-known drugs like anticoagulants, antihypertensives, antiserotoninergics, and so also with viral proteases. We here report a brief list of these drugs (i.e., heparinoids, flavonoids, antiplatelets, anticoagulants) that may interact with COVID-19.
Downloads
PlumX Metrics
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
Citations
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.